GBD 2017 Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England) 392(10159):1736–1788. https://doi.org/10.1016/s0140-6736(18)32203-7

Article  Google Scholar 

D’Agostino R, Vasan R, Pencina M et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. 117(6):743–753. https://doi.org/10.1161/circulationaha.107.699579

Perk J, Graham I, De Backer GJH (2014) Prevention of cardiovascular disease: new guidelines, new tools, but challenges remain. 2014; 100(9):675–677. https://doi.org/10.1136/heartjnl-2014-305650

Kantor E, Rehm C, Haas J, Chan A, Giovannucci EJJ (2015) Trends in prescription drug use among adults in the United States from 1999–2012. 314(17):1818–1831. https://doi.org/10.1001/jama.2015.13766

Pedersen T, Kjekshus J, Berg K et al (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 2004;5(3):81 – 7. https://doi.org/10.1016/j.atherosclerosissup.2004.08.027

Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. 380(9841):581–590. https://doi.org/10.1016/s0140-6736(12)60367-5

Stone N, Robinson J, Lichtenstein A et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. 63:2889–2934. https://doi.org/10.1016/j.jacc.2013.11.002

Grundy SM, Stone NJ, Bailey AL et al (2019) AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(25):e1082–e143. https://doi.org/10.1161/cir.0000000000000625

Article  PubMed  Google Scholar 

Mehra VM, Gaalema DE, Pakosh M, Grace SL (2020) Systematic review of cardiac rehabilitation guidelines: quality and scope. Eur J Prev Cardiol 27(9):912–928. https://doi.org/10.1177/2047487319878958

Article  PubMed  Google Scholar 

Chou R, Cantor A, Dana T et al (2022) Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 328(8):754–771. https://doi.org/10.1001/jama.2022.12138

Article  PubMed  Google Scholar 

Schonberger RB, Vallurupalli V, Matlin H et al (2020) Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. Prev Med Rep 18:101085. https://doi.org/10.1016/j.pmedr.2020.101085

Article  PubMed  PubMed Central  Google Scholar 

Onaisi R, Dumont R, Hasselgard-Rowe J et al (2022) Multimorbidity and statin prescription for primary prevention of cardiovascular diseases: a cross-sectional study in general practice in France. Front Med 9:1089050. https://doi.org/10.3389/fmed.2022.1089050

Article  Google Scholar 

Metser G, Bradley C, Moise N et al (2021) Gaps and disparities in primary prevention statin prescription during outpatient care. Am J Cardiol 161:36–41. https://doi.org/10.1016/j.amjcard.2021.08.070

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zipf G, Chiappa M, Porter K et al National health and nutrition examination survey: plan and operations, 1999–2010. 2013(56):1–37

Schwartz G, Olsson A, Ezekowitz M et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. 285(13):1711–1718. https://doi.org/10.1001/jama.285.13.1711

Serruys P, de Feyter P, Macaya C et al (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. 287(24):3215–3222. https://doi.org/10.1001/jama.287.24.3215

Shepherd J, Cobbe S, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotl Coron Prev Study Group 333(20):1301–1307. https://doi.org/10.1056/nejm199511163332001

Article  CAS  Google Scholar 

Colhoun H, Betteridge D, Durrington P et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. 364(9435):685–696. https://doi.org/10.1016/s0140-6736(04)16895-5

Byrne P, Demasi M, Jones M et al (2022) Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. 182(5):474–481. https://doi.org/10.1001/jamainternmed.2022.0134

Weintraub W, Lüscher T, Pocock SJE (2015) The perils of surrogate endpoints. 36(33):2212–2218. https://doi.org/10.1093/eurheartj/ehv164

Silverman M, Ference B, Im K et al (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. 316(12):1289–1297. https://doi.org/10.1001/jama.2016.13985

Savelieva I, Kourliouros A, Camm J (2010) Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 381(3):1–13. https://doi.org/10.1007/s00210-009-0468-y

Article  CAS  PubMed  Google Scholar 

JA (2019) ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2019;290:140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014

Rosengren AJEhj (2012) Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? 33(5):562–563. https://doi.org/10.1093/eurheartj/ehr364

Wessel A, Gravenhorst V, Buchhorn R et al (2004) Risk of sudden death in the Williams-Beuren syndrome. Am J Med Genet Part A 127a(3):234–237. https://doi.org/10.1002/ajmg.a.30012

Article  PubMed  Google Scholar 

Lewington S, Whitlock G, Clarke R et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. 370(9602):1829–1839. https://doi.org/10.1016/s0140-6736(07)61778-4

Grundy S, Stone N, Bailey A, NLA/PCNA Guideline on the Management of Blood Cholesterol (2019) A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. 139(25):e1082–e143. https://doi.org/10.1161/cir.0000000000000625. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/

Fulcher J, O’Connell R, Voysey M et al (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. 385(9976):1397–1405. https://doi.org/10.1016/s0140-6736(14)61368-4

Antza C, Gallo A, Boutari C et al (2023) Prevention of cardiovascular disease in young adults: focus on gender differences. A collaborative review from the EAS Young fellows. Atherosclerosis 384:117272. https://doi.org/10.1016/j.atherosclerosis.2023.117272

Article  CAS  PubMed  Google Scholar 

Holven KB, van Roeters J (2023) Sex differences in lipids: a life course approach. Atherosclerosis 384:117270. https://doi.org/10.1016/j.atherosclerosis.2023.117270

Article  CAS  PubMed  Google Scholar 

Bosco G, Di Giacomo Barbagallo F, Di Marco M et al (2024) The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia. Front Endocrinol 15:1346152. https://doi.org/10.3389/fendo.2024.1346152

Article  Google Scholar 

Carnethon M, Pu J, Howard G et al (2017) Cardiovascular health in African Americans: a scientific statement. Am Heart Association 136(21):e393–e423. https://doi.org/10.1161/cir.0000000000000534

Article  Google Scholar 

Gujral U, Vittinghoff E, Mongraw-Chaffin M et al (2017) Cardiometabolic abnormalities among normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional analysis of two cohort studies. 166(9):628–636. https://doi.org/10.7326/m16-1895

Article  Google Scholar 

Benner J, Glynn R, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. 288(4):455–461. https://doi.org/10.1001/jama.288.4.455

Global regional et al (2016) and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). ;388(10053):1659 – 724. https://doi.org/10.1016/s0140-6736(16)31679-8

Roelfs DJ, Shor E, Kalish R, Yogev T (2011) The rising relative risk of mortality for singles: meta-analysis and meta-regression. Am J Epidemiol 174(4):379–389. https://doi.org/10.1093/aje/kwr111

Article  PubMed  Google Scholar